Skip to main content
Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Investment Managers
Sector Finance
Employees 3,987
CEO Mr. Elias J. Sabo
Address 301 Riverside Avenue 2nd Floor, Westport, CT 06880
Phone 1.203.221.1703
Website compassdiversified.com

Compass Diversified Holdings invests in small and middle-market companies in the US with an EBITDA of at least $15 million per annum. The fund targets companies operating in product manufacturing, electronic technology, consumer durables, consumer non-durables, health technology, industrial services. Its transaction size ranges from $100 million to $800 million. They make control investments and provide financing for buyout transactions. They also invest in public companies.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
Compass Diversified Holdings 5.57% 54.80%
Erie Indemnity Co. 20.23% -10.31%
Jefferies Financial Group, Inc. 6.34% 66.51%
Credicorp Ltd. 13.77% -22.43%
Alleghany Corp. 0.74% 13.43%

Statement Summary

as of 1:10 ET PM 11/26/2021
Total Assets (MRQ) 2.8 B
Total Liabilities (MRQ) 1.6 B
Shareholders’ Equity (MRQ) 1.2 B
Total Revenue (Annual) 488.2 M
Net Income (Annual) -499.0 K

Earnings And Estimates

as of 1:10 ET PM 11/26/2021

Current Qtr EPS Estimate 0.55
Current FY EPS Estimate 2.61
Long Term EPS Growth Estimate 7.00
Next Expected Earnings Date 3/2/2022

CODI vs S&P 500

as of 11/26/2021
Relative To
S&P 500
CODI
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 1:10 ET PM 11/26/2021
Fiscal Quarter Estimate Actual Surprise
09/2021 0.49 0.65 +32.49%
06/2021 0.46 0.72 +56.09%
03/2021 0.38 0.67 +77.19%
12/2020 0.37 0.55 +50.47%
09/2020 0.26 0.67 +160.42%
06/2020 0.06 0.22 +242.64%
03/2020 0.24 0.29 +22.82%
12/2019 0.43 0.50 +16.44%

Financial Strength

as of 1:10 ET PM 11/26/2021
Pre-Tax Margin 5.79
Net Margin -95.99
Operating Margin 8.57
Return On Equity -0.06
Return On Assets -0.02
Inventory Turnover (TTM) 2.99
Sales Growth (MRQ) 14.15

Ratios

as of 1:10 PM ET 11/26/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 2.69
Price/Cash Flow (TTM) 10.72
Book Value (MRQ) 11.23
Quick Ratio (MRQ) 1.10
Current Ratio (MRQ) 2.51
Total Debt/Equity (MRQ) 1.19

Short Interest

as of 9:32 AM ET 11/29/2021
% Short - 1.02%
% Remaining Float - 98.98%
Current Last Month
Short Interest Date 11/15/2021 10/29/2021
Short Interest Shares 560,613 299,436
Short Interest Ratio 3.9 2.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 1:10 ET PM 11/26/2021
Current Qtr
(12/2021)
Next Qtr
(03/2022)
Consensus Estimate $0.55 $0.59
# of Estimates 4 4
High Estimate $0.64 $0.68
Low Estimate $0.42 $0.49
Year Ago EPS $-0.02 $0.01
Year Over Year Growth Estimate -2,808.33% 4,580.00%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $2.61 $2.62
# of Estimates 4 4
High Estimate $2.72 $2.90
Low Estimate $2.41 $2.23
Year Ago EPS $1.75 $2.61
Year Over Year Growth Estimate 48.97% 0.19%
Current Qtr
(12/2021)
Next Qtr
(03/2022)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $0.55 $0.59 $2.61 $2.62
# of Estimates 4 4 4 4
High Estimate $0.64 $0.68 $2.72 $2.90
Low Estimate $0.42 $0.49 $2.41 $2.23
Year Ago EPS $-0.02 $0.01 $1.75 $2.61
Year Over Year Growth Estimate -2,808.33% 4,580.00% 48.97% 0.19%

Insider Information Summary

as of 10/31/2021
% Insiders - 15.40%
% Remaining Total Shares - 84.60%
Current 1 Month
Net Insider Transaction 41.72 K 41.72 K
Shares Bought 58.72 K 58.72 K
Shares Sold 17.00 K 17.00 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Covid-19 Vaccine Lead

'Vaccine' Chosen as Word of The Year

The 202I prize for Merriam-Webster’s Word of the Year went to an obvious choice: vaccine.

Stronger Yen Sends Nissan's Profits South

Nissan to Invest Over $17 Billion in EVs Over Next 5 Years

Nissan hopes to roll out 23 new electric vehicle models by 2030.

Patty Hearst NFT Lead

NFTs: Patty Hearst Court Drawing, USS Arizona Mapping to Be Auctioned

NFTs: A courtroom drawing from the trial of kidnapped heiress Patty Hearst and an illustrated mapping of the USS Arizona are up for auction.

Elon Musk, founder of Tesla and SpaceX, brought attention on the Clubhouse to new heights after hosting a conversation on the audio social app. Photo: AFP

Musk Urges Tesla Staff to Watch Costs, Keep Cool on Deliveries

'Our focus this quarter should be on minimizing cost of deliveries rather than spending heavily ... just so that cars arrive in Q4,' he said.

Cyber Monday Results Rolling In -- Here Are the Brands Facing Pressure

Cyber Monday Discounts Cut Due to Lean Inventories: Adobe

Consumers are expected to spend between $10.2 billion and $11.3 billion on Cyber Monday, Adobe said.

Twitter Blue Lead

Twitter CEO Jack Dorsey Steps Down, CTO Parag Agrawal Named As Replacement

Twitter confirmed Monday that co-founder Jack Dorsey will step down as CEO, with chief technology Parag Agrawal named as his replacement.

Hyatt Hotel Lead

Hyatt Shares Rise on J.P. Morgan Upgrade to Overweight

'We are using the 10% pullback from share price levels earlier in the month to get more aggressive on Hyatt,' the bank writes.

Brett Biggs Walmart CFO Lead

Walmart CFO Brett Biggs Leaving After 22 Years

Walmart says Biggs stay on as CFO until a successor is named and will remain as an associate until he leaves in January 2023.

Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know

Bristol Myers Stock Falls Despite Positive News on Psoriasis Drug

Bristol Myers shares fall after the FDA accepts its psoriasis-treating deucravacitinib drug application, and European regulators also validate its application.

Is Best Buy Stock an Investor Best Buy After Earnings Beat? -- The Charts Speak

Best Buy, Big-Box Store Inventory Strong, Roku Demand High: Wedbush

Wedbush finds no shortage of in-store inventory for consumer electronics. And it says Roku products are in strong demand.